In 2011, Bayer and Johnson & Johnson introduced Xarelto as a new generation anticoagulant (blood thinner) medication for use in preventing blood clots in atrial fibrillation patients and after knee or hip replacement surgery.
What made Xarelto special was that it was a once-a-day pill that would not require constant blood monitoring like traditional anticoagulant meds (such as warfarin). The problem with Xarelto was that it caused excessive bleeding and, unlike other blood thinners, there was no available antidote or reversal agent to stop excessive bleeding caused by Xarelto.
As a result, many people who were taking Xarelto experienced excessive bleeding or internal hemorrhaging that could not be easily stopped. This fundamental problem with Xarelto eventually resulted in a mass of product liability lawsuits alleging that the drug makers failed to adequately warn about Xarelto’s risk of uncontrollable bleeding. There are currently over 21,000 Xarelto lawsuits pending in federal and state courts.